This book’s focus is on Alzheimer’s, the many additional diseases that cause dementia and the reasons for the lack of drugs to treat these neurological dysfunctions. Suggested changes to the USA’s Food and Drug Administration (FDA) protocols are offered in order to accelerate the drug development pipeline and reduce the huge costs required to conduct human clinical trials. The importance of the brain renin-angiotensin system is described and possible new directions in drug development are discussed, along with the changing role of academic researchers in identifying and developing new treatment strategies. The book was written for those families touched by Alzheimer’s and other dementias, academic scientists interested in neurodegenerative diseases, and would-be entrepreneurs considering beginning a start-up company.
Mai multe cărți electronice de la același autor (i) / Editor
77.452 Ebooks din această categorie
